In bio­phar­ma, most part­ner­ships do not fail be­cause of val­u­a­tion. They fail be­cause crit­i­cal as­sump­tions, around ex­e­cu­tion, reg­u­la­to­ry align­ment, sup­ply re­li­a­bil­i­ty, or man­u­fac­tur­ing readi­ness, are sur­faced too late. By the time a term sheet is signed, many of the fac­tors that ul­ti­mate­ly de­ter­mine suc­cess or fail­ure have al­ready been im­plic­it­ly de­cid­ed.

As de­vel­op­ment pro­grams be­come more com­plex and glob­al from ear­li­er stages, this re­al­i­ty is be­com­ing in­creas­ing­ly ev­i­dent. Suc­cess­ful part­ner­ships to­day are less about ne­go­ti­at­ing the “per­fect” deal and more about align­ing ear­ly on how that deal will ac­tu­al­ly be ex­e­cut­ed.

This is why, in our ex­pe­ri­ence, the most ef­fec­tive glob­al part­ner­ships of­ten be­gin well be­fore the term sheet.

Glob­al bio­phar­ma part­ner­ships now op­er­ate in an en­vi­ron­ment de­fined by reg­u­la­to­ry di­ver­gence, in­creas­ing scruti­ny on qual­i­ty and sup­ply ro­bust­ness, and height­ened ex­pec­ta­tions around man­u­fac­tur­ing re­li­a­bil­i­ty. These con­sid­er­a­tions are no longer con­fined to late-stage as­sets; they in­flu­ence part­ner­ing de­ci­sions much ear­li­er in de­vel­op­ment.

In this con­text, the lo­ca­tion and reg­u­la­to­ry en­vi­ron­ment of man­u­fac­tur­ing be­come strate­gic vari­ables. Op­er­at­ing with­in high­ly reg­u­lat­ed frame­works brings clear ad­van­tages: pre­dictable qual­i­ty stan­dards, stronger reg­u­la­to­ry cred­i­bil­i­ty, sup­ply re­li­a­bil­i­ty, and greater trans­paren­cy across the val­ue chain. Over time, these fac­tors trans­late not on­ly in­to re­duced op­er­a­tional risk, but al­so in­to greater cost ef­fi­cien­cy by min­i­miz­ing de­vi­a­tions, re­work, and reg­u­la­to­ry fric­tion.

For Busi­ness De­vel­op­ment teams, this com­plex­i­ty cre­ates a dilem­ma. Wait­ing too long to en­gage can mean dis­cov­er­ing mis­align­ment on­ly when time­lines and re­sources are al­ready com­mit­ted. En­gag­ing too ear­ly, on the oth­er hand, is some­times per­ceived as pre­ma­ture.

In prac­tice, ear­ly en­gage­ment, when struc­tured cor­rect­ly, is of­ten the most ef­fec­tive way to man­age these risks.

Be­fore any for­mal agree­ment is in place, ex­pe­ri­enced BD teams tend to fo­cus on a con­sis­tent set of ques­tions:

• Is there a clear and re­al­is­tic de­vel­op­ment and reg­u­la­to­ry strat­e­gy across re­gions?
• Can man­u­fac­tur­ing and sup­ply be sus­tained re­li­ably un­der strict reg­u­la­to­ry over­sight?
• How ma­ture are the qual­i­ty sys­tems sup­port­ing long-term com­mer­cial sup­ply?
• Is there open­ness to adapt de­vel­op­ment plans to spe­cif­ic part­ner and mar­ket needs?

These ques­tions can­not be ful­ly an­swered in a da­ta room. They re­quire di­a­logue, con­text, and of­ten a de­gree of co-de­sign that on­ly emerges through ear­ly in­ter­ac­tion.

Ex­plorato­ry, non-bind­ing frame­works cre­ate space for this align­ment. They al­low both par­ties to clar­i­fy as­sump­tions, un­der­stand con­straints, and iden­ti­fy op­por­tu­ni­ties for op­ti­miza­tion be­fore com­mer­cial terms be­come the fo­cus.

One of the clear­est lessons we have learned is that as­sets de­signed for ear­ly part­ner­ing per­form bet­ter once de­vel­op­ment ac­cel­er­ates. Ear­ly agree­ments en­able true co-de­vel­op­ment, al­low­ing both com­pa­nies to shape de­vel­op­ment strate­gies around re­al mar­ket, reg­u­la­to­ry, and sup­ply re­quire­ments.

When part­ners en­gage at an ear­ly stage, de­vel­op­ment plans can be tai­lored to:

• Spe­cif­ic reg­u­la­to­ry path­ways
• Re­gion­al mar­ket ex­pec­ta­tions
• Man­u­fac­tur­ing and sup­ply strate­gies aligned from the out­set

This flex­i­bil­i­ty is dif­fi­cult, and of­ten cost­ly, to in­tro­duce lat­er. Ear­ly part­ner­ing al­lows both sides to in­vest re­sources more ef­fi­cient­ly, avoid re­dun­dant ac­tiv­i­ties, and fo­cus de­vel­op­ment ef­forts where they add the most val­ue.

Our ap­proach to part­ner­ing is shaped by ex­pe­ri­ence. Sup­port­ing glob­al launch­es of com­plex biosim­i­lars re­quires far more than tech­ni­cal de­vel­op­ment ex­cel­lence. It de­mands con­sis­tent qual­i­ty per­for­mance, strong reg­u­la­to­ry align­ment, and man­u­fac­tur­ing op­er­a­tions ca­pa­ble of sup­ply­ing mul­ti­ple mar­kets re­li­ably over time.

Hav­ing sup­port­ed glob­al launch­es of biosim­i­lars such as be­va­cizum­ab and deno­sum­ab, we have seen first-hand how ear­ly align­ment be­tween part­ners in­flu­ences long-term out­comes. In these pro­grams, suc­cess was dri­ven by de­ci­sions tak­en ear­ly, around de­vel­op­ment strat­e­gy, reg­u­la­to­ry po­si­tion­ing, sup­ply plan­ning, and gov­er­nance, rather than by late-stage ne­go­ti­a­tions.

This ex­pe­ri­ence now in­forms us how we ex­pand our port­fo­lio and how we ap­proach new glob­al part­ner­ing op­por­tu­ni­ties. It re­in­forces a sim­ple prin­ci­ple: ex­e­cu­tion readi­ness, when es­tab­lished ear­ly, re­duces risk for every­one in­volved.

An­oth­er im­por­tant as­pect of ear­ly part­ner­ing lies in the abil­i­ty to op­ti­mize de­vel­op­ment path­ways. In cer­tain cas­es, ear­ly align­ment be­tween part­ners and reg­u­la­tors may en­able the use of Phase 3 waivers or stream­lined clin­i­cal strate­gies, sig­nif­i­cant­ly re­duc­ing de­vel­op­ment time­lines and over­all costs.

These op­por­tu­ni­ties can on­ly be re­al­is­ti­cal­ly as­sessed when part­ners en­gage ear­ly enough to joint­ly eval­u­ate reg­u­la­to­ry op­tions, com­pa­ra­bil­i­ty strate­gies, and da­ta re­quire­ments. When dis­cus­sions be­gin too late, these ef­fi­cien­cies are of­ten no longer avail­able.

Ear­ly agree­ments, even on a non-bind­ing ba­sis, cre­ate the frame­work for these eval­u­a­tions. They al­low com­pa­nies to ex­plore al­ter­na­tive de­vel­op­ment ap­proach­es col­lab­o­ra­tive­ly, align­ing sci­en­tif­ic, reg­u­la­to­ry, and com­mer­cial con­sid­er­a­tions from the out­set.

The most suc­cess­ful part­ner­ships rarely start with a con­tract. They start with the right con­ver­sa­tions, con­ver­sa­tions that hap­pen ear­ly enough to shape out­comes rather than re­act to them.

As port­fo­lios ex­pand and glob­al com­plex­i­ty in­creas­es, the abil­i­ty to en­gage ear­ly, open­ly, and prag­mat­i­cal­ly is be­com­ing a strate­gic ad­van­tage. For BD teams on both sides of the ta­ble, em­brac­ing this mind­set can make the dif­fer­ence be­tween deals that look good on pa­per and part­ner­ships that de­liv­er in prac­tice.

To learn more about mAbx­ience's biosim­i­lar port­fo­lio and glob­al part­ner­ing ap­proach, vis­it www.mabx­ience.com.